Answers are grounded in this paper and cite their sources.
The SYK-AKT1/E-cadherin regulatory axis exhibits subtype-restricted functional pleiotropy in breast cancer pathogenesis. However, its opposing oncogenic versus tumor-suppressive roles across molecular subtypes reflect a functional dichotomy whose molecular determinants remain incompletely defined. This study elucidates the subtype-specific mechanisms by which this axis modulates breast cancer cell invasion and migration. Pan-cancer SYK expression analysis across 33 TCGA tumor types was integrated with gene set enrichment analysis (GSEA). SYK was depleted by siRNA or overexpressed via pEX-3-SYK transfection in Luminal A (MCF-7) and Basal-like/ triple-negative (MDA-MB-231) cell lines. Immunoblotting quantified SYK, PI3K/AKT effectors (p-AKT1 Ser473 , p-mTOR Ser2448 ), and EMT markers (E-cadherin, N-cadherin). Apoptosis and cell cycle distribution were assessed by flow cytometry; Transwell assays measured invasive capacity. SYK/AKT1 co-overexpression is an independent prognostic biomarker predicting poor overall survival in Luminal A breast cancer. Mechanistically, SYK upregulation correlated inversely with AKT1, p-AKT1 Ser473 , and E-cadherin protein abundance in Luminal A models, concomitant with attenuated PI3K/AKT activation, migration, and invasion. Conversely, SYK overexpression enhanced motility in Basal-like models, revealing context-dependent functional antagonism. Collectively, these data establish the potentially SYK-AKT1 axis as a subtype-selective regulator of invasion and migration in Luminal A breast cancer, rationalizing combinatorial pharmacologic inhibition of SYK and PI3K/AKT.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: